In vivo correction of cystic fibrosis mediated by PNA nanoparticles is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2022). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 1K99HL151806-01A1
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis
National Institutes of Health
Grant: 1F32HL142144-01
Developing Poly(amine-co-ester) Polymeric Delivery Vehicles and 3D Culture Screening Platforms for the Treatment of Hereditary Beta-thalassemia with Peptide Nucleic Acid Genome Editing Technology
National Institutes of Health
Grant: 5R01HL125892-04
Targeted correction of the human CFTR gene
National Institutes of Health
Grant: 1UG3HL147352-01
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
National Institutes of Health
Grant: 2T32GM086287-16
Research Training in Anesthesia
Fields of Study
Keywords
Sustainable Development Goals